I have researched and tried so many products and prescriptions and this is the only product that has worked for me. You may have to experiment a bit to get the right dosage, but stay with it. Clear directions and suggested dosages and uses are helpful. I didn’t have side effects with this product unlike prescriptions. I am grateful for this product and so glad I found your website.
Thank you.

• About Us

• My Account

• Products

• Helpful Info

* Applies only to orders $100 or more shipping US Domestic Shipping. Shipping & handling is by lowest carrier rate possible within the Continental United States. Orders below $100 may still take advantage of our $5.99 US Domestic flat rate shipping.
** Excluding: All Equipment, Apex Products, Therasage Products, and other select items.

It should come as no surprise that Menoquil works as well as it does when you look at the key active ingredients that the leading researchers at Pharmaxa Labs have included in this powerful formula. The all-natural blend combines proven botanicals such as Black Cohosh, Soy Isoflavones, and Chaste Berry, all included in their optimal concentrations and specifically designed to work synergistically for maximum results. And, unlike some menopause relief supplements, Menoquil contains absolutely no hormones or synthetic substances so there’s no danger of side effects, even with extended use.

Estro-500 is manufactured by Natural Living Company, a company based in Las Vegas, NV. They have been in business since 2006 and are known for manufacturing several different vitamins, dietary supplements, and cosmetic creams.

All products manufactured by the Natural Living Company are made in the U.S. according to GMP specifications.

Estro-500 Review – Health Web Magazine Images

We offer a buying guide for estro 500, and we provide 100% genuine and unbiased information. We make use of Big Data and AI data to proofread the information. How has this buying guide been made? We have a uniquely designed set of algorithms, which enable us to make a list of top 10 estro 500 that are available in the marketplace these days. Our technology of bringing together a list depends on the factors such as:

How To Buy Best estro 500

Does shopping for the best estro 500 get stressful for you? Are doubts rolling over your head and confusing you? We know how it is; we have been through the entire journey of estro 500 research as we have put forward an entire list of the best estro 500 available in the market these days. We have brainstormed a few questions that most of you might have in mind.

Although there may be more than what we are suggesting here, it is significant for you to ensure that you conduct exclusive research for this product before buying it for yourself. The questions may include:

• Is a estro 500 worth the purchase?
• What are the advantages of buying a estro 500?
• What factors should you consider before shopping for the best estro 500?
• Why is it important to invest in a estro 500, especially the best one?
• What are the good estro 500 available in today’s market? Or what is the best estro 500 in 2022?

And, where would you get all this kind of information? We are absolutely sure that you may have many more questions, and the best way to quench your thirst is to get them all solved from various online resources. Sources may be anything such as online forums, word-of-mouth, rating websites, buying guides, and product reviews. Proper research is essential before buying the best estro 500 for yourself. Ensure that you are reading from highly reliable, trustworthy websites or any other sources.

We offer a buying guide for estro 500, and we provide 100% genuine and unbiased information. We make use of Big Data and AI data to proofread the information. How has this buying guide been made? We have a uniquely designed set of algorithms, which enable us to make a list of top 10 estro 500 that are available in the marketplace these days. Our technology of bringing together a list depends on the factors such as:

1. Brand Value
2. Features & Specifications
3. Product Value
4. Customer Reviews & Ratings
5. Quality and Durability

We do not forget that keeping product information up-to-date is our priority; therefore, we keep our websites updated at all times. Get more information about us through online sources. If you feel that the information displayed here is misleading or is incorrect or is irrelevant from actual facts, then please do not hesitate to get in touch with us. We will be there for you at all times!

Lepidium meyenii (extract 4:1). 150 mg

Estro-X

Mood, weight gain, appetite and even overall health are greatly affected by estrogen.

Unfortunately, there are still many people who believe that we should eliminate estrogen, it should rather help to be better metabolized and balanced with other hormones (such as progesterone).

The human body is equipped with mechanisms that should hypothetically take care of balancing these hormones, but they sometimes need a little support to function optimally.

CONTRAINDICATIONS: If you are pregnant or breastfeeding, do not use this product.
CAUTIONS AND WARNINGS: If you are taking medications or natural health products, consult a healthcare practitioner prior to use. If you are attempting to conceive, consult a healthcare practitioner prior to use. If you have liver disorder or symptoms associated with low estrogen levels (such as joint pain, mood changes, changes in libido, hot flashes, night sweats, vaginal dryness or irregular menstruations), consult a healthcare practitioner prior to use. If you develop liver-related symptoms (e.g. yellowing of the eyes and/or skin, dark urine, abdominal pain, jaundice), or symptoms associated with low estrogen levels, consult a healthcare practitioner. To exclude the diagnosis of a serious cause of hormonal imbalance, consult a healthcare practitioner prior to use. If symptoms persistor worsen, consult a healthcare practitioner. If you are taking medications, consult a healthcare practitioner since Resveratrol may alter the effectiveness of these medications. If you have high blood pressure or if you are taking blood thinner or if you are taking antidepressants, consult a healthcare practitioner prior to use. Discontinue use and consult a health care practitioner if you are experiencing a persistent gastrointestinal disorder and / or nausea. Discontinue use if you experience joint pain or flushing. Consumption in combination with alcoholic beverages or any other medicinal product or natural health product with sedative effects is not recommended. Mood, weight gain, appetite and even overall health are greatly affected by estrogen. Unfortunately, there are still many people who believe that we should eliminate estrogen, it should rather help to be better metabolized and balanced with other hormones (such as progesterone). The human body is equipped with mechanisms that should hypothetically take care of balancing these hormones, but they sometimes need a little support to function optimally.

RECOMMENDED DOSE: Adults: 1 capsule, 1 time per day.

DURATION OF USE: For use beyond 3 months, consult a healthcare practitioner.

MEDICINAL INGREDIENTS (per capsule)

Lepidium meyenii (extract 4:1). 150 mg

Equivalent to 0.6 g of Maca roots

Calcium D-Glucarate (Calcium saccharate). 150 mg

Centella asiatica (extract 30 : 1). 125 mg

Equivalent to 3750 mg of Gotu kola whole plant

3,3’-Diindolylmethane (DIM). 80 mg

Resveratrol. 60 mg

Grape seed extract (extract 5:1). 30 mg

Equivalent to 150 mg of Vitis vinifera seeds (proanthocyanide oligomeric 85%)

NON-MEDICINAL INGREDIENTS:

Hypromellose, L-leucine, magnesium stearate, Oryza Sativa powder (rice).

Therapeutic hormonal support formula

Mood, weight gain, appetite and even overall health are greatly affected by estrogen.

Unfortunately, there are still many people who believe that we should eliminate estrogen, it should rather help to be better metabolized and balanced with other hormones (such as progesterone).

The human body is equipped with mechanisms that should hypothetically take care of balancing these hormones, but they sometimes need a little support to function optimally.

CONTRAINDICATIONS: If you are pregnant or breastfeeding, do not use this product.
CAUTIONS AND WARNINGS: If you are taking medications or natural health products, consult a healthcare practitioner prior to use. If you are attempting to conceive, consult a healthcare practitioner prior to use. If you have liver disorder or symptoms associated with low estrogen levels (such as joint pain, mood changes, changes in libido, hot flashes, night sweats, vaginal dryness or irregular menstruations), consult a healthcare practitioner prior to use. If you develop liver-related symptoms (e.g. yellowing of the eyes and/or skin, dark urine, abdominal pain, jaundice), or symptoms associated with low estrogen levels, consult a healthcare practitioner. To exclude the diagnosis of a serious cause of hormonal imbalance, consult a healthcare practitioner prior to use. If symptoms persistor worsen, consult a healthcare practitioner. If you are taking medications, consult a healthcare practitioner since Resveratrol may alter the effectiveness of these medications. If you have high blood pressure or if you are taking blood thinner or if you are taking antidepressants, consult a healthcare practitioner prior to use. Discontinue use and consult a health care practitioner if you are experiencing a persistent gastrointestinal disorder and / or nausea. Discontinue use if you experience joint pain or flushing. Consumption in combination with alcoholic beverages or any other medicinal product or natural health product with sedative effects is not recommended. Mood, weight gain, appetite and even overall health are greatly affected by estrogen. Unfortunately, there are still many people who believe that we should eliminate estrogen, it should rather help to be better metabolized and balanced with other hormones (such as progesterone). The human body is equipped with mechanisms that should hypothetically take care of balancing these hormones, but they sometimes need a little support to function optimally.

RECOMMENDED DOSE: Adults: 1 capsule, 1 time per day.

DURATION OF USE: For use beyond 3 months, consult a healthcare practitioner.

MEDICINAL INGREDIENTS (per capsule)

Lepidium meyenii (extract 4:1). 150 mg

Equivalent to 0.6 g of Maca roots

Calcium D-Glucarate (Calcium saccharate). 150 mg

Centella asiatica (extract 30 : 1). 125 mg

Equivalent to 3750 mg of Gotu kola whole plant

3,3’-Diindolylmethane (DIM). 80 mg

Resveratrol. 60 mg

Grape seed extract (extract 5:1). 30 mg

Equivalent to 150 mg of Vitis vinifera seeds (proanthocyanide oligomeric 85%)

Each gram of ESTRACE ® (estradiol vaginal cream, USP, 0.01%) contains 0.1 mg estradiol in a nonliquefying base containing purified water, propylene glycol, stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose 2208 (4000 cps), sodium lauryl sulfate, methylparaben, edetate di-sodium and tertiary-butylhydroquinone. Estradiol is chemically described as estra-1,3,5(10)-triene- 3,17β-diol. It has an empirical formula of C₁₈H₂₄O₂ and molecular weight of 272.37. The structural formula is:

Estrace Vaginal Cream

Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses (see WARNINGS, Malignant neoplasms, Endometrial cancer).

CARDIOVASCULAR AND OTHER RISKS

Estrogens with or without progestins should not be used for the prevention of cardiovascular disease (see WARNINGS, Cardiovascular Disorders).

The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see CLINICAL PHARMACOLOGY, Clinical Studies ).

The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens-plus-medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen-alone therapy (see CLINICAL PHARMACOLOGY, Clinical Studies ).

Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DESCRIPTION

Each gram of ESTRACE ® (estradiol vaginal cream, USP, 0.01%) contains 0.1 mg estradiol in a nonliquefying base containing purified water, propylene glycol, stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose 2208 (4000 cps), sodium lauryl sulfate, methylparaben, edetate di-sodium and tertiary-butylhydroquinone. Estradiol is chemically described as estra-1,3,5(10)-triene- 3,17β-diol. It has an empirical formula of C₁₈H₂₄O₂ and molecular weight of 272.37. The structural formula is:

INDICATIONS

ESTRACE (estradiol vaginal cream, USP, 0.01%) is indicated in the treatment of vulvar and vaginal atrophy.

DOSAGE AND ADMINISTRATION

Use of ESTRACE (estradiol vaginal cream, USP, 0.01%), alone or in combination with a progestin, should be limited to the shortest duration consistent with treatment goals and risks for the individual woman. Patients should reevaluate periodically as clinically appropriate (for example, 3-month to 6- month intervals) to determine if treatment is still necessary (see BOX WARNING and WARNINGS). For treatment of vulvar and vaginal atrophy associated with the menopause, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible. For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.

Attempts to discontinue or taper medication should be made at 3-month to 6-month intervals.

Usual Dosage

The usual dosage range is 2 to 4 g (marked on the applicator) daily for one or two weeks, then gradually reduced to one half initial dosage for a similar period. A maintenance dosage of 1 g, one to three times a week, may be used after restoration of the vaginal mucosa has been achieved.

NOTE: The number of doses per tube will vary with dosage requirements and patient handling.

HOW SUPPLIED

ESTRACE ® (estradiol vaginal cream, USP, 0.01%)

N 0430-3754-14: Tube containing 1 ½ oz (42.5 g) with a calibrated plastic applicator for delivery of 1, 2, 3, or 4 g.

Store at room temperature. Protect from temperatures in excess of 40° C (104° F).

Keep ESTRACE Vaginal Cream out of the reach of children.

Manufactured by: Contract Pharmaceuticals Limited, Mississauga, Ontario, Canada L5N 6L6. Revised: June 2016

QUESTION

SIDE EFFECTS

Systemic absorption may occur with the use of ESTRACE (estradiol vaginal cream, USP, 0.01%). The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account.

The following additional adverse reactions have been reported with estrogen and/or progestin therapy.

Genitourinary System

Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; dysmenorrhea, increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; application site reactions of vulvovaginal discomfort including burning and irritation; genital pruritus; ovarian cancer; endometrial hyperplasia; endometrial cancer.

Breasts

Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer.

Cardiovascular

Gastrointestinal

Nausea, vomiting; abdominal cramps, bloating; cholestatic jaundice; increased incidence of gallbladder disease; pancreatitis, enlargement of hepatic hemangiomas.

Chloasma or melasma, that may persist when drug is discontinued; erythema multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; pruritus, rash.

Retinal vascular thrombosis, intolerance to contact lenses.

Central Nervous System

Headache; migraine; dizziness; mental depression; chorea; nervousness; mood disturbances; irritability; exacerbation of epilepsy, dementia.

Miscellaneous

Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; arthralgias; leg cramps; changes in libido; urticaria, angioedema, hypersensitivity, anaphylactoid/anaplylactic reactions; hypocalcemia; exacerbation of asthma; increased triglycerides.

DRUG INTERACTIONS

1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VIIX complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
2. Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T₄ levels (by column or by radioimmunoassay) or T₃ levels by radioimmunoassay. Patients on thyroid replacement therapy may require higher doses of thyroid hormone. T₃ resin uptake is decreased, reflecting the elevated TBG. Free T₄ and free T₃ concentrations are unaltered.
3. Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased circulating corticosteroids and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
4. Increased plasma HDL and HDL₂ subfraction concentrations, reduced LDLcholesterol concentration, increased triglycerides levels. .
5. Reduced response to metyrapone test.
6. Reduced serum folate concentration.

WARNINGS

Systemic absorption may occur with the use of ESTRACE (estradiol vaginal cream, USP, 0.01%). The warnings, precautions, and adverse reactions associated with oral estrogen treatment should be taken into account.

Cardiovascular Disorders

Estrogen and estrogen/progestin therapy has been associated with an increased risk of cardiovascular events such as myocardial infarction and stroke, as well as venous thrombosis and pulmonary embolism (venous thromboembolism or VTE). Should any of these occur or be suspected, estrogens should be discontinued immediately.

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.

Coronary Heart Disease And Stroke

In the Women’s Health Initiative (WHI) study, an increase in the number of myocardial infarctions and strokes has been observed in women receiving CE compared to placebo. These observations are preliminary, and the study is continuing (see CLINICAL PHARMACOLOGY, Clinical Studies ).

In the CE/MPA substudy of WHI, an increased risk of coronary heart disease (CHD) events (defined as nonfatal myocardial infarction and CHD death) was observed in women receiving CE/MPA compared to women receiving placebo (37 versus 30 per 10,000 women-years). The increase in risk was observed in year one and persisted.

In the same substudy of WHI, an increased risk of stroke was observed in women receiving CE/MPA compared to women receiving placebo (29 versus 21 per 10,000 women-years). The increase in risk was observed after the first year and persisted.

In postmenopausal women with documented heart disease (n = 2,763, average age 66.7 years) a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS) treatment with CE/MPA (0.625 mg/2.5 mg per day) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE/MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE/MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand three hundred and twenty one women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE/MPA group and the placebo group in HERS, HERS II, and overall.

Large doses of estrogen (5 mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast, have been shown in a large prospective clinical trial in men to increase the risks of nonfatal myocardial infarction, pulmonary embolism, and thrombophlebitis.

Venous Thromboembolism (VTE)

In the Women’s Health Initiative (WHI) study, an increase in VTE has been observed in women receiving CE compared to placebo. These observations are preliminary, and the study is continuing (see CLINICAL PHARMACOLOGY, Clinical Studies ).

In the CE/MPA substudy of WHI, a 2-fold greater rate of VTE, including deep venous thrombosis and pulmonary embolism, was observed in women receiving CE/MPA compared to women receiving placebo. The rate of VTE was 34 per 10,000 women-years in the CE/MPA group compared to 16 per 10,000 women-years in the placebo group. The increase in VTE risk was observed during the first year and persisted.

If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.

Malignant Neoplasms

Endometrial Cancer

The use of unopposed estrogens in women with intact uteri has been associated with an increased risk of endometrial cancer. The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than one year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24- fold for five to ten years or more and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.

Clinical surveillance of all women taking estrogen/progestin combinations is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.

Breast Cancer

The use of estrogens and progestins by postmenopausal women has been reported to increase the risk of breast cancer. The most important randomized clinical trial providing information about this issue is the Women’s Health Initiative (WHI) substudy of CE/MPA (see CLINICAL PHARMACOLOGY, Clinical Studies). The results from observational studies are generally consistent with those of the WHI clinical trial and report no significant variation in the risk of breast cancer among different estrogens or progestins, doses, or routes of administration.

The CE/MPA substudy of WHI reported an increased risk of breast cancer in women who took CE/MPA for a mean follow-up of 5.6 years. Observational studies have also reported an increased risk for estrogen/progestin combination therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. In the WHI trial and from observational studies, the excess risk increased with duration of use. From observational studies, the risk appeared to return to baseline in about five years after stopping treatment. In addition, observational studies suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen/progestin combination therapy as compared to estrogen-alone therapy.

In the CE/MPA substudy, 26 percent of the women reported prior use of estrogen-alone and/or estrogen/progestin combination hormone therapy. After a mean follow-up of 5.6 years during the clinical trial, the overall relative risk of invasive breast cancer was 1.24 (95 percent confidence interval 1.01 to 1.54), and the overall absolute risk was 41 versus 33 cases per 10,000 women-years for CE/MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years for CE/MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE/MPA compared with placebo. In the same substudy, invasive breast cancers were larger and diagnosed at a more advanced stage in the CE/MPA group compared with the placebo group. Metastatic disease was rare with no apparent difference between the two groups. Other prognostic factors such as histologic subtype, grade and hormone receptor status did not differ between the groups.

The use of estrogen-plus-progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.

Dementia

In the Women’s Health Initiative Memory Study (WHIMS), 4,532 generally healthy postmenopausal women 65 years of age and older were studied, of whom 35 percent were 70 to 74 years of age and 18 percent were 75 or older. After an average follow-up of 4 years, 40 women being treated with CE/MPA (1.8 percent, n = 2,229) and 21 women in the placebo group (0.9 percent, n = 2,303) received diagnoses of probable dementia. The relative risk for CE/MPA versus placebo was 2.05 (95 percent confidence interval 1.21 to 3.48), and was similar for women with and without histories of menopausal hormone use before WHIMS. The absolute risk of probable dementia for CE/MPA versus placebo was 45 versus 22 cases per 10,000 women-years, and the absolute excess risk for CE/MPA was 23 cases per 10,000 women-years. It is unknown whether these findings apply to younger postmenopausal women (see CLINICAL PHARMACOLOGY, Clinical Studies and PRECAUTIONS, Geriatric Use).

It is unknown whether these findings apply to estrogen-alone therapy.

Gallbladder Disease

A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.

Hypercalcemia

Estrogen administration may lead to severe hypercalcemia in patients with breast cancer and bone metastases. If hypercalcemia occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.

Visual Abnormalities

Retinal vascular thrombosis has been reported in patients receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, estrogens should be permanently discontinued.